On Friday, Following stocks ended their trade in “Green-Zone“: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), Juno Therapeutics Inc. (NASDAQ:JUNO), Apollo Commercial Real Estate Finance, Inc. (NYSE:ARI), UBS Group AG (NYSE:UBS)

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), with shares inclined 3.11%, closed at $4.15.

Juno Therapeutics Inc. (NASDAQ:JUNO),with shares jumped 3.10%, settled at $61.53, hitting new 52-week high of $62.50.

Apollo Commercial Real Estate Finance, Inc. (NYSE:ARI), with shares climbed 3.09%, and closed at $17.67, hitting new 52-week high of $17.69.

UBS Group AG (NYSE:UBS), surged 3.09%, and closed at $18.70, hitting new 52-week high of $18.84.

Latest NEWS regarding these Stocks are depicted underneath:

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals, Inc. (SGYP), stated its financial results and business update for the fourth quarter and the year ended December 31, 2014.

In the recent development, On January 8, 2015 and January 29, 2015, the company declared that they had accomplished patient enrollment in the first and second of two pivotal phase 3 trials, respectively, which are evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC). Each trial is a randomized, 12-week, double-blind, placebo-controlled phase 3 trial evaluating plecanatide, once-daily oral tablets, in about 1350 adult patients with CIC. The company expect to release top-line data results from the first phase 3 CIC trial in the second quarter of 2015, and top-line results from the second phase 3 CIC trial in the third quarter of 2015. In the fourth quarter of this year, the company plan to file their first new drug application (NDA) with the FDA for plecanatide to treat CIC.

Synergy Pharmaceuticals Inc., a biopharmaceutical corporation, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders, in addition to is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders.

Juno Therapeutics Inc. (NASDAQ:JUNO)

Juno Therapeutics Inc. (JUNO), stated business highlights and financial results for the fourth quarter and year ended December 31, 2014.

The company declared:

Positive momentum and progress on clinical trials continues, Strong year-end cash position of $474.1 million, 2015 cash burn guidance of $125 million to $150 million, not including cash inflows or outflows from business development activities and ongoing litigation.

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical corporation focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer.

Apollo Commercial Real Estate Finance, Inc. (NYSE:ARI)

Apollo Commercial Real Estate Finance, Inc. (ARI), declared the Board of Directors has declared a cash dividend on the Corporation’s 8.625% Series A Cumulative Redeemable Perpetual Preferred Stock of $0.5391 per share for the quarterly period ending on April 15, 2015. The preferred dividend is payable on April 15, 2015 to preferred stockholders of record as of March 31, 2015.

Apollo Commercial Real Estate Finance, Inc. (ARI) is a real estate investment trust that primarily originates, invests in, attains and manages performing commercial first mortgage loans, subordinate financings, CMBS and other commercial real estate-related debt investments.

UBS Group AG (NYSE:UBS)

UBS Wealth Administration Americas, a division of UBS Group AG (UBS), renamed its retirement plan consulting business, UBS Retirement Plan Consulting Services , to better reflect the corporation’s service offering, and noteworthy commitment to the business and its plan sponsor clients. The business had formerly been known as the DC Advisory Program.

With a shifting environment and ongoing regulatory changes, counting potential new DOL fiduciary rules, retirement plans face growing complexity and increasingly seek consulting services. As part of their commitment to serve this market, UBS Retirement Plan Consulting Services recently conducted extensive research into the changing industry landscape and evolving client needs to ensure they deliver services that meet the needs of today’s plan sponsors. Leveraging insights gained from plan sponsor feedback, the business has developed a keen focus on what plan sponsors value and desire in a consultant. UBS Retirement Plan Consulting Services provides sponsors with:

• Customized advice and a roadmap for managing plan complexity
• An practiced and dedicated Retirement Plan Consultant delivering advice through a firm with extensive resources and capital strength
• Retirement plan consulting capabilities, coupled with our broad financial experience to assist manage today’s challenges for both plan sponsors and participants.

UBS Group AG, together with its auxiliaries, provides wealth administration, retail and corporate, asset administration, and investment banking products and services worldwide.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.